On Tuesday, Daiichi Sankyo Company, Limited (4568:JP) (OTC: DSNKY) shares maintained a positive outlook as TD Cowen sustained its Buy rating and JPY46.00 price target on the company's stock.

(RTTNews) - Merck & Co., Inc. (MRK) and Daiichi Sankyo (DSKYF.PK) announced that an interim analysis of the dose-optimization phase of the ongoing IDeate-Lung01 Phase 2 trial shows ifinatamab ...

Six late-breaking presentations across lung and breast cancer trials of DXd ADCs, including two Presidential Symposia at WCLC featuring datopotamab deruxtecan data First ever clinical data from ...

2,3 Patient comorbidities and frailty may unnecessarily affect CVD management. 4,5,6 Daiichi Sankyo remains committed to its promise to continue expanding medical knowledge to support better CV ...

Data at WCLC and ESMO showcasing Daiichi Sankyo’s progress towards its goal of creating new standards of care for patients with cancer will include six late-breaking presentations, including two ...

Daiichi Sankyo will present new clinical research across its antibody drug conjugate (ADC) portfolio with more than 25 abstracts across multiple types of cancer at the IASLC 2024 World Conference on ...

On Wednesday, Jefferies, a global investment banking firm, updated its outlook on shares of Daiichi Sankyo Company, Limited (4568:JP) (OTC: DSNKY), raising the price target to JPY7,600 from JPY6,600.

Daiichi Sankyo and AstraZeneca are padding the case for their antibody-drug conjugate Enhertu with new data demonstrating the medicine’s worth in patients whose cancer has spread to the brain.

Shares of AstraZeneca Plc and Daiichi Sankyo Co. tumbled after the pair’s lung cancer drug showed mixed results in a late-stage trial. Astra dropped as much as 5.4% in early London trading ...

AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has failed to improve overall survival (OS) in non-small cell lung cancer (NSCLC), extending the list of molecules ...

WILMINGTON, Del. - AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo's datopotamab deruxtecan (Dato-DXd) has shown a trend toward improving overall survival (OS) compared with chemotherapy in a Phase ...